Data from preclinical studies conducted to examine the activities of the novel estrogen receptor beta (ERbeta) agonist EGX-358, previously under study for the treatment of hot flushes at Estrigenix Therapeutics, for the potential treatment of Alzheimer's disease (AD) were presented at the recent Alzheimer's Association International Conference.
It has been previously demonstrated that MYCN amplification frequently occurs in high-risk neuroblastoma (NB), and it is correlated with an undifferentiated phenotype and poor prognosis.
Helios-Huaming BioPharma has synthesized new substituted salicylamide compounds acting as protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis and ischemia-reperfusion injury, among other disorders.
Yale University has presented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
Shanghai Hengrui Pharmaceutical and Jiangsu Hengrui Medicine have described cyclohexadiimide derivatives reported to be useful for the treatment of cancer and neurological disorders.
Beijing Erai Therapeutics has identified aminoheteroaryl compounds acting as mitochondrial brown fat uncoupling protein 1 (UCP1) activators reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes and obesity.
Clade C subtype-specific HIV-1 infections are responsible for over 48% of global HIV-1 burden. Aiming to develop a vaccine that provides heterologous protection against HIV, a research group led by investigators from the Emory Vaccine Center at Emory University recently reported a novel clade C HIV-1 vaccine.
Many pathogens such as HIV, SARS-CoV-2, or those linked to influenza or cholera infect the host through mucosal surfaces and thus are thought to require both systemic and mucosal immune responses for effective management and protection.
RSS